HK1133642A1 - Azaadamantane ester and carbamate derivatives and methods of use thereof - Google Patents

Azaadamantane ester and carbamate derivatives and methods of use thereof

Info

Publication number
HK1133642A1
HK1133642A1 HK10100761.5A HK10100761A HK1133642A1 HK 1133642 A1 HK1133642 A1 HK 1133642A1 HK 10100761 A HK10100761 A HK 10100761A HK 1133642 A1 HK1133642 A1 HK 1133642A1
Authority
HK
Hong Kong
Prior art keywords
ester
methods
azaadamantane
carbamate derivatives
compounds
Prior art date
Application number
HK10100761.5A
Other languages
English (en)
Inventor
Michael R Schrimpf
Diana L Nersesian
Kevin B Sippy
Jianguo Ji
Tao Li
Lei Shi
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1133642A1 publication Critical patent/HK1133642A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10100761.5A 2007-03-23 2010-01-22 Azaadamantane ester and carbamate derivatives and methods of use thereof HK1133642A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89674507P 2007-03-23 2007-03-23
PCT/US2008/057641 WO2008118742A1 (en) 2007-03-23 2008-03-20 Azaadamantane ester and carbamate derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1133642A1 true HK1133642A1 (en) 2010-04-01

Family

ID=39788934

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100761.5A HK1133642A1 (en) 2007-03-23 2010-01-22 Azaadamantane ester and carbamate derivatives and methods of use thereof

Country Status (10)

Country Link
US (2) US8163916B2 (es)
EP (1) EP2129672B1 (es)
JP (2) JP5566698B2 (es)
CN (2) CN103145711A (es)
AT (1) ATE509931T1 (es)
CA (1) CA2679870A1 (es)
ES (1) ES2363998T3 (es)
HK (1) HK1133642A1 (es)
MX (1) MX2009010174A (es)
WO (1) WO2008118742A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
RU2549551C2 (ru) * 2009-06-19 2015-04-27 Эббви Инк. Производные диазагомоадамантана и способы их применения
EP2389922A1 (en) * 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
JP5838498B2 (ja) * 2010-05-25 2016-01-06 シムライズ アーゲー 皮膚及び／又は毛髪のライトニング活性物質としてのシクロヘキシルカルバメート化合物
WO2010097479A2 (en) * 2010-05-25 2010-09-02 Symrise Gmbh & Co. Kg Cyclohexyl carbamate compounds as active anti-cellulite ingredients
WO2012040404A1 (en) 2010-09-23 2012-03-29 Abbott Laboratories Monohydrate of an azaadamantane derivative
WO2014164682A1 (en) 2013-03-12 2014-10-09 Abbvie Inc. Azaadamantane formate ester and process preparing azaadamantane derivatives
US20170166561A1 (en) 2014-07-11 2017-06-15 Alpharmagen, Llc Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
WO2016201096A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8523211D0 (en) * 1985-09-19 1985-10-23 Beecham Group Plc Compounds
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
EP0329932B1 (en) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
US5140023A (en) * 1990-04-27 1992-08-18 G. D. Searle & Co. Azatetracycle compounds
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5521193A (en) * 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) * 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
WO1995021820A1 (fr) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
EP1125922A1 (en) * 1998-11-02 2001-08-22 Welfide Corporation Pyrrolidine compounds and medicinal utilization thereof
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
JP4616971B2 (ja) * 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
WO2008096870A1 (ja) * 2007-02-09 2008-08-14 Astellas Pharma Inc. アザ架橋環化合物

Also Published As

Publication number Publication date
ES2363998T3 (es) 2011-08-22
US20080255178A1 (en) 2008-10-16
CN101641355A (zh) 2010-02-03
JP2014205695A (ja) 2014-10-30
CN103145711A (zh) 2013-06-12
CA2679870A1 (en) 2008-10-02
US8163916B2 (en) 2012-04-24
EP2129672A1 (en) 2009-12-09
MX2009010174A (es) 2009-10-12
JP2010522201A (ja) 2010-07-01
EP2129672A4 (en) 2009-12-09
US20120190704A1 (en) 2012-07-26
WO2008118742A1 (en) 2008-10-02
ATE509931T1 (de) 2011-06-15
EP2129672B1 (en) 2011-05-18
JP5566698B2 (ja) 2014-08-06

Similar Documents

Publication Publication Date Title
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
JOP20180102B1 (ar) مركب صيدلاني
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
MY153915A (en) Organic compounds
NO20090596L (no) Antivirale fosfinatforbindelser
TW200806280A (en) Pharmaceutical compositions
JO2778B1 (en) Certain vehicles, installations and methods
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2009156484A3 (en) Organic compounds
IN2014DN09346A (es)
MY148253A (en) Azaadamantane derivatives and methods of use
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
TW200640924A (en) VEGF-R2 inhibitors and methods
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
TW200634023A (en) Amide prodrug of gemcitabine, compositions and use thereof
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
EP2557919A4 (en) STABILIZED FORMULATIONS OF STATIN
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
TN2009000510A1 (en) Extended release formulation of nevirapine
SG158091A1 (en) Imidazoazepinone compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150320